Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls

Onkologie

Volumn 30, Issue 11, 2007, Pages 559-563

  Petrova, D T ^a   Yaramov, N ^b   Toshev, S ^b   Nedeva, P ^c   Maslyankov, S ^c   Von Ahsen, N ^d   Oellerich, M ^d   Toncheva, D ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^c Specialized Oncological Hospital   (Bulgaria)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Bulgarian population; Colorectal cancer; Cytochrome P450; Polymorphisms

Indexed keywords

CYTOCHROME P450 3A5;

AGED; ARTICLE; BULGARIA; CANCER PATIENT; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE PROBE; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION;

AGED; BULGARIA; COLORECTAL NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 36049014937     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108285     Document Type: Article

References (38)

1. Gill S, Sinicrope FA: Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? Semin Oncol 2005;32:24-34.
2. Mader RM: Links between biology, prognosis and prediction of response to chemotherapy in colorectal cancer. Onkologie 2006;29:334-341.
3. Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl J Med 2003;348:919-932.
4. Benet LZ, Cummins CL, Wu CY: Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003;4:393-398.
5. de la Chapelle A: Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004;4:769-780.
6. Windmill KF, McKinnon RA, Zhu X, Gaedigk A, Grant DM, McManus ME: The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res 1997;376:153-160.
7. Wu WK, Wong HP, Luo SW, Chan K, Huang FY, Hui MK, Lam EK, Shin VY, Ye YN, Yang YH, Cho CH: 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone from cigarette smoke stimulates colon cancer growth via beta-adrenoceptors. Cancer Res 2005;65:5272-5277.
8. Denissenko MF, Pao A, Tang M, Pfeifer GP: Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-432.
9. Kivistö KT, Kroemer HK, Eichelbaum M: The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995;40:523-530.
10. Nebert DW, Russell DW: Clinical importance of the cytochromes P450. Lancet 2002;360:1155-1162.
11. Guengerich FP: Cytochromes P450, drugs, and diseases. Mol Interv 2003;3:194-204.
12. Murray GI: The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol 2000;192:419-426.
13. Chen JK, Wang DW, Falck JR, Capdevila J, Harris RC: Transfection of an active cytochrome P450 arachidonic acid epoxygenase indicates that 14,15-epoxyeicosatrienoic acid functions as an intracellular second messenger in response to epidermal growth factor. J Biol Chem 1999;274:4764-4769.
14. Juchau MR, Boutelet-Bochan H, Huang Y: Cytochrome-P450-dependent biotransformation of xenobiotics in human and rodent embryonic tissues. Drug Metab Rev 1998;30:541-568.
15. Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271-1294.
16. Jounaidi Y, Hyrailles V, Gervot L, Maurel P: Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem Biophys Res Commun 1996;221:466-470.
17. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391.
18. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-779.
19. Antonarakis SE: Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 1998;11:1-3.
20. Petrova DT, Nedeva P, Maslyankov S, Toshev S, Yaramov N, Atanasova S, Toncheva D, Oellerich M, von Ahsen N: No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol 2007;DOI:10.1007/s00432-007-0279-9 (in print).
21. Compton CC, Greene FL: The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004;54:295-308.
22. Raichev R: Morphological Diagnostics of the Tumors. Sofia, Medicine and Physical Culture Press, 1983.
23. Atanasova SY, von Ahsen N, Toncheva DI, Dimitrov TG, Oellerich M, Armstrong VW: Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN). Clin Biochem 2005;38:223-228.
24. von Ahsen N, Oellerich M, Armstrong VW, Schutz E: Application of a thermodynamic nearest-neighbor model to estimate nucleic acid stability and optimize probe design: prediction of melting points of multiple mutations of apolipoprotein B-3500 and factor V with a hybridization probe genotyping assay on the LightCycler. Clin Chem 1999;45:2094-2101.
25. Abramson JH, Gahlinger PM: Computer Programs for Epidemiologists: PEPI Version 3.00. Llanidloes, Brixton Books, 1999.
26. Christensen K: Population Genetics, ed 2. PDF Book, 2002, pp 11-12, www.kursus.kvl.dk/shares/vetgen/_Popgen/genetics/genetik.pdf.
27. Danielson PB: The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002;3:561-597.
28. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.
29. Ding X, Kaminsky LS: Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003;43:149-173.
30. Sempoux C, Starkel P, Stevens M, Van Den Berge V, Horsmans Y: Cytochrome P450 3A proteins are expressed in B lymphocytes but not in T lymphocytes. Pharmacogenetics 1999;9:263-265.
31. McKay JA, Murray GI, Weaver RJ, Ewen SW, Melvin WT, Burke MD: Xenobiotic metabolising enzyme expression in colonic neoplasia. Gut 1993;34:1234-1239.
32. Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S, Murray GI: Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res 2005;11:3758-3765.
33. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A: CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004;75:1059-1069.
34. He P, Court MH, Greenblatt DJ, von Moltke LL: Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos 2006;34:1198-1207.
35. Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A: Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 2005;11:7398-7404.
36. Garsa AA, McLeod HL, Marsh S: CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet 2005;6:19.
37. CYP3A5 allele nomenclature: www.cypalleles.ki.se/cyp3a5.htm.
38. Electronic database information: www.ncbi.nlm.nih.gov/entrez/query. fcgi?CMD=search&DB=snp.